Treatment of Severe Atopic Dermatitis with Omalizumab: Experience of a Portuguese Immunoallergology Department

Methods Twenty-four patients (14 male 10 female) 30,8 year-old average with severe AD,allergic respiratory disease and high levels of IgE (>2000 UI/L) not responding to conventional therapies were proposed for omalizumab treatment.They were evaluated for SCORAD index and daily/rescue medication b...

Full description

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2016-02, Vol.137 (2), p.AB149-AB149
Main Authors: Mendes, Ana M., MD, Pestana, Leticia, MD, Aguiar, Rita, MD, Costa, Ana Célia, MSc, Pedro, Elisa, MD, Lopes, Anabela, MD, Spinola Santos, Maria A., MD, Alonso, Estrella, MD, Pereira-Barbosa, M.A., PhD
Format: Article
Language:English
Subjects:
Allergies
Allergy and Immunology
Dermatitis
Patients
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Methods Twenty-four patients (14 male 10 female) 30,8 year-old average with severe AD,allergic respiratory disease and high levels of IgE (>2000 UI/L) not responding to conventional therapies were proposed for omalizumab treatment.They were evaluated for SCORAD index and daily/rescue medication before,during and after treatment.Omalizumab was administrated subcutaneously at doses range from 150 to 600 mg every 2 weeks for 19,6 months average treatment.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2015.12.616